These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 17371293)

  • 1. The neuronal pathology of schizophrenia: molecules and mechanisms.
    Reynolds GP; Harte MK
    Biochem Soc Trans; 2007 Apr; 35(Pt 2):433-6. PubMed ID: 17371293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The biological basis of schizophrenia: new directions.
    Weinberger DR
    J Clin Psychiatry; 1997; 58 Suppl 10():22-7. PubMed ID: 9265913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neural basis of psychosis-related behaviour in the infection model of schizophrenia.
    Meyer U; Feldon J
    Behav Brain Res; 2009 Dec; 204(2):322-34. PubMed ID: 19154759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased vulnerability to depressive-like behavior of mice with decreased expression of VGLUT1.
    Garcia-Garcia AL; Elizalde N; Matrov D; Harro J; Wojcik SM; Venzala E; Ramírez MJ; Del Rio J; Tordera RM
    Biol Psychiatry; 2009 Aug; 66(3):275-82. PubMed ID: 19409534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in vesicular transporters for gamma-aminobutyric acid and glutamate reveal vulnerability and reorganization of hippocampal neurons following pilocarpine-induced seizures.
    Boulland JL; Ferhat L; Tallak Solbu T; Ferrand N; Chaudhry FA; Storm-Mathisen J; Esclapez M
    J Comp Neurol; 2007 Jul; 503(3):466-85. PubMed ID: 17503488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment.
    Mouri A; Noda Y; Enomoto T; Nabeshima T
    Neurochem Int; 2007; 51(2-4):173-84. PubMed ID: 17669558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium binding protein markers of GABA deficits in schizophrenia--postmortem studies and animal models.
    Reynolds GP; Abdul-Monim Z; Neill JC; Zhang ZJ
    Neurotox Res; 2004; 6(1):57-61. PubMed ID: 15184106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of cortical inhibition in the pathophysiology and treatment of schizophrenia.
    Daskalakis ZJ; Fitzgerald PB; Christensen BK
    Brain Res Rev; 2007 Dec; 56(2):427-42. PubMed ID: 17980435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced N-acetylaspartate in the temporal cortex of rats reared in isolation.
    Harte MK; Powell SB; Reynolds LM; Swerdlow NR; Geyer MA; Reynolds GP
    Biol Psychiatry; 2004 Aug; 56(4):296-9. PubMed ID: 15312819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implication of neuronal Ca2+ -sensor protein VILIP-1 in the glutamate hypothesis of schizophrenia.
    Gierke P; Zhao C; Bernstein HG; Noack C; Anand R; Heinemann U; Braunewell KH
    Neurobiol Dis; 2008 Oct; 32(1):162-75. PubMed ID: 18691652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypothesis: minimal changes in neural transmission in schizophrenia: decreased glutamatergic and GABAergic functions in the prefrontal cortex.
    Ohnuma T; Suzuki T; Arai H
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jul; 29(6):889-94. PubMed ID: 15949884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A two-process theory of schizophrenia: evidence from studies in post-mortem brain.
    Deakin JF; Simpson MD
    J Psychiatr Res; 1997; 31(2):277-95. PubMed ID: 9278190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications.
    Gaspar PA; Bustamante ML; Silva H; Aboitiz F
    J Neurochem; 2009 Nov; 111(4):891-900. PubMed ID: 19686383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between aberrant neuronal activation in the pregenual anterior cingulate, altered glutamatergic metabolism, and anhedonia in major depression.
    Walter M; Henning A; Grimm S; Schulte RF; Beck J; Dydak U; Schnepf B; Boeker H; Boesiger P; Northoff G
    Arch Gen Psychiatry; 2009 May; 66(5):478-86. PubMed ID: 19414707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GABA and schizophrenia: a review of basic science and clinical studies.
    Wassef A; Baker J; Kochan LD
    J Clin Psychopharmacol; 2003 Dec; 23(6):601-40. PubMed ID: 14624191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The importance of synapsin I and II for neurotransmitter levels and vesicular storage in cholinergic, glutamatergic and GABAergic nerve terminals.
    Bogen IL; Haug KH; Roberg B; Fonnum F; Walaas SI
    Neurochem Int; 2009; 55(1-3):13-21. PubMed ID: 19428802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How do glial-neuronal interactions fit into current neurotransmitter hypotheses of schizophrenia?
    Kondziella D; Brenner E; Eyjolfsson EM; Sonnewald U
    Neurochem Int; 2007 Jan; 50(2):291-301. PubMed ID: 17084946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nitric oxide and brain hyperexcitability.
    Ferraro G; Sardo P
    In Vivo; 2004; 18(3):357-66. PubMed ID: 15341192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis.
    Enomoto T; Noda Y; Nabeshima T
    Methods Find Exp Clin Pharmacol; 2007 May; 29(4):291-301. PubMed ID: 17609743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New morphological and neuropathological findings in schizophrenia: a neurodevelopmental perspective.
    Bunney BG; Potkin SG; Bunney WE
    Clin Neurosci; 1995; 3(2):81-8. PubMed ID: 7583623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.